{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:05:07Z","timestamp":1765422307631,"version":"3.37.3"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Light chain (AL) amyloidosis is a form of systemic amyloidosis, causing organ dysfunction, mainly affecting the heart and kidney. Patient-tailored and risk-adapted decision making is critical in AL amyloidosis management. There is limited real-world evidence data from Argentina and Latin America regarding the treatment approaches for AL amyloidosis. This retrospective cohort study aimed to describe the treatment patterns and outcomes in adult patients (&gt;18 years) diagnosed with AL amyloidosis at the Hospital Italiano in Buenos Aires, Argentina, using a 10-yearfollow-up data (June 1, 2010 to May 31, 2019) from the institutional registry of amyloidosis (IRA). The study population had a mean age of 63 years and 54.4% weremale. Heart and kidney were the most frequently affected organs. Of the 90 eligible patients included in the study, 70underwent treatment. Bortezomib-based regimen was the preferred first-line treatment (75.7% patients). Overall,54.4% of the patients presented a deep response (complete or very good partial response). Median overall survival (OS) was 5years, the 1-year OS and progression free survival rates were 80% (95% confidence interval [CI]: 68\u201387) and 80% (95%CI 68\u201387)), respectively. This study provides vital real-world evidence for the long-term treatment patterns and survival in a large cohort of AL amyloidosis patients in Argentina.<\/jats:p>","DOI":"10.1371\/journal.pone.0274578","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T17:56:24Z","timestamp":1666893384000},"page":"e0274578","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-7069","authenticated-orcid":true,"given":"Maria Lourdes","family":"Posadas-Martinez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-2284","authenticated-orcid":true,"given":"Mar\u00eda Adela","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Brulc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Soledad","family":"Saez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Sorroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Machnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1742-1448","authenticated-orcid":true,"given":"Mariana","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa Mercedes","family":"Nucifora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"issue":"2","key":"pone.0274578.ref001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"G Palladini","year":"2016","journal-title":"Blood"},{"issue":"10","key":"pone.0274578.ref002","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/j.clml.2019.09.558","article-title":"Estimating the Global Epidemiology of Amyloid Light-Chain Amyloidosis With an Incidence-to-Prevalence Model","volume":"19","author":"N Zhang","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"pone.0274578.ref003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-4-47","article-title":"Light chain (AL) amyloidosis: update on diagnosis and management","volume":"4","author":"M Rosenzweig","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"10","key":"pone.0274578.ref004","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"TP Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"pone.0274578.ref005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13506129.2016.1207626","article-title":"Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort","volume":"23","author":"MA Aguirre","year":"2016","journal-title":"Amyloid"},{"issue":"1","key":"pone.0274578.ref006","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"R. Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"11","key":"pone.0274578.ref007","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14779072.2015.1093936","article-title":"Novel strategies for the diagnosis and treatment of cardiac amyloidosis","volume":"13","author":"G Palladini","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"8","key":"pone.0274578.ref008","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3324\/haematol.2009.008912","article-title":"Current treatment of AL amyloidosis","volume":"94","author":"G Palladini","year":"2009","journal-title":"Haematologica"},{"key":"pone.0274578.ref009","article-title":"European medicines agency","author":"EMA","year":"2020","journal-title":"Public summary of opinion on orphan designation; Chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4 for the treatment of AL amyloidosis"},{"year":"2016","author":"AMC","journal-title":"Guidance for Industry AL Amyloidosis\u2014Developing Drugs for Treatment","key":"pone.0274578.ref010"},{"issue":"2","key":"pone.0274578.ref011","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"AD Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0274578.ref012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"E Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0274578.ref013","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation","volume":"110","author":"V Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"6","key":"pone.0274578.ref014","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"MM Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"year":"2013","author":"National Comprehensive Cancer Network","journal-title":"NCCN clinical practice guidelines in oncology; Systemtic light chain amyloidosis","key":"pone.0274578.ref015"},{"issue":"3","key":"pone.0274578.ref016","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"M Skinner","year":"1996","journal-title":"Am J Med"},{"issue":"28","key":"pone.0274578.ref017","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"38","author":"E Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0274578.ref018","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case\u2013control study on 174 patients","volume":"28","author":"G Palladini","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"pone.0274578.ref019","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"SV Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"36","key":"pone.0274578.ref020","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes","volume":"30","author":"G Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0274578.ref021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"MA Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"14","key":"pone.0274578.ref022","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: Pathogenesis and New Therapeutic Options","volume":"29","author":"G Merlini","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0274578.ref023","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","article-title":"AL amyloidosis: advances in diagnostics and treatment","volume":"34","author":"R. Ry\u0161av\u00e1","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"pone.0274578.ref024","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure","volume":"9","author":"UA Tahir","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"pone.0274578.ref025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis","volume":"7","author":"CD Barrett","year":"2019","journal-title":"JACC Hear Fail"},{"issue":"00","key":"pone.0274578.ref026","first-page":"1):1","article-title":"Clinical profile and treatment outcome of older (&gt;75 years) patients with systemic AL amyloidosis","volume":"1;","author":"S Sachchithanantham","year":"]. 2","journal-title":"Haematologica"},{"issue":"5","key":"pone.0274578.ref027","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten\u2010year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"E Muchtar","year":"2019","journal-title":"Br J Haematol"},{"issue":"25","key":"pone.0274578.ref028","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"R Manwani","year":"2019","journal-title":"Blood"},{"issue":"3","key":"pone.0274578.ref029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","article-title":"Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: a multicentric retrospective study and review of the literature","volume":"27","author":"R Lecumberri","year":"2020","journal-title":"Amyloid"},{"issue":"5","key":"pone.0274578.ref030","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"G Palladini","year":"2015","journal-title":"Blood"},{"issue":"7","key":"pone.0274578.ref031","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"GP Kaufman","year":"2017","journal-title":"Blood"},{"issue":"18","key":"pone.0274578.ref032","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"V Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"1","key":"pone.0274578.ref033","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"G Palladini","year":"2020","journal-title":"Blood"},{"issue":"5","key":"pone.0274578.ref034","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s41375-019-0664-9","article-title":"Revisiting complete response in light chain amyloidosis","volume":"34","author":"S Sidana","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"pone.0274578.ref035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.16094","article-title":"Lessons in Long Term Survival from AL Amyloidosis","volume":"187","author":"JM Sloan","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"pone.0274578.ref036","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2012.274","article-title":"Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis","volume":"27","author":"H Landau","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"pone.0274578.ref037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis","volume":"141","author":"I Vaxman","year":"2019","journal-title":"Acta Haematol"},{"key":"pone.0274578.ref038","first-page":"1239","article-title":"AL amyloidosis in the Chilean public health system: a pending debt. Multicenter study of the Chilean Monoclonal Gammopathies Cooperative Group","volume":"147","author":"C Pe\u00f1a","year":"2019","journal-title":"Art\u00edculos Investig"},{"issue":"6","key":"pone.0274578.ref039","first-page":"604","article-title":"Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: A single institution, 30-year experience","volume":"64","author":"J Hern\u00e1ndez-Reyes","year":"2012","journal-title":"Rev Investig Clin"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T17:57:04Z","timestamp":1666893424000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274578"}},"subtitle":[],"editor":[{"given":"Benigno C.","family":"Valdez","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0274578","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}